2. Protein Tyrosine Kinase/RTK MAPK/ERK Pathway Autophagy
  3. VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie
  4. Regorafenib mesylate

Regorafenib mesylate  (Synonyms: BAY 73-4506 mesylate)

Cat. No.: HY-10331B
Handling Instructions

Molarity Calculator

Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity.

For research use only. We do not sell to patients.

Regorafenib mesylate Chemical Structure

Regorafenib mesylate Chemical Structure

CAS No. : 835621-08-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Regorafenib mesylate:

Other Forms of Regorafenib mesylate:

Regorafenib mesylate Related Antibodies

Top Publications Citing Use of Products

47 Publications Citing Use of MCE Regorafenib mesylate

WB

    Regorafenib mesylate purchased from MedChemExpress. Usage Cited in: Neoplasia. 2023 Mar 18;39:100897.  [Abstract]

    Regorafenib (0-40 µM; 36 h) markedly increases the expression of cleaved caspase-3, while decreases the expression of anti-apoptotic protein Bcl-2, in both H1299 and PC-9 cells.

    Regorafenib mesylate purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2018 Sep 25;19(10). pii: E2915.  [Abstract]

    Effects on the expression of phosphorylated extracellular signal-related kinase (p-ERK), ERK, thymidylate synthase (TS), and markers of cell death in SW620, HCT 116, and HT-29 cells using various Regorafenib treatment schedules.

    Regorafenib mesylate purchased from MedChemExpress. Usage Cited in: Br J Cancer. 2017 Sep 26;117(7):974-983.  [Abstract]

    The effect of the AKT inhibitor MK2206 (10 μM) on the expression levels of phosphor-AKT, AKT, and STMN1 in TKI-pretreated NCI-H460 cells. β-actin is used as a loading control.

    View All VEGFR Isoform Specific Products:

    View All Isoforms
    VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

    View All PDGFR Isoform Specific Products:

    View All Isoforms
    PDGFR PDGFRβ PDGFRα

    View All Raf Isoform Specific Products:

    View All Isoforms
    BRaf c-Raf Raf

    View All FGFR Isoform Specific Products:

    View All Isoforms
    FGFR FGFR1 FGFR2 FGFR3 FGFR4 FGF21

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity[1].

    IC50 & Target

    Tie2

    311 ± 46 nM (IC50)

    Raf-1

    2.5 ± 0.6 nM (IC50)

    VEGFR2

    4.2 ± 1.6 nM (IC50)

    VEGFR1

    13 ± 0.4 nM (IC50)

    BRafV600E

    19 ± 6 nM (IC50)

    PDGFRβ

    22 ± 3 nM (IC50)

    B-Raf

    28 ± 10 nM (IC50)

    VEGFR3

    46 ± 10 nM (IC50)

    In Vitro

    Regorafenib mesylate (0-10 μM, 96 h) shows anti-proliferation activity in GIST 882, Thyroid TT, MDA-MB-231, HepG2, A375 and SW620 cells[1].
    Regorafenib mesylate (0-3000 nM, 30 min) inhibits the autophosphorylation of VEGFR2, TIE2 and PDGFR-β, and inhibits FGFR and pERK1/2[1].
    Regorafenib mesylate causes a concentration-dependent decrease in Hep3B cell growth, with an IC50 of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Regorafenib mesylate Related Antibodies

    Cell Proliferation Assay[1]

    Cell Line: GIST 882, Thyroid TT, MDA-MB-231, HepG2, A375 and SW620 cells
    Concentration: 10 μM and 5 nM
    Incubation Time: 96 h
    Result: Showed anti-proliferation activity in GIST 882, Thyroid TT, MDA-MB-231, HepG2, A375 and SW620 cells, with IC50 values of 45 ± 20, 34 ± 8, 401 ± 88, 560 ± 200, 900, 967 ± 287 nM. respectively.

    Western Blot Analysis[1]

    Cell Line: NIH-3T3/VEGFR2 cells, (CHO)-TIE2 cells, HAoSMCs cells, MCF-7 cells
    Concentration: 0, 10, 30, 100, 300, 1000, 3000 nM
    Incubation Time: 30 min
    Result: Inhibited the autophosphorylation of VEGFR2, TIE2 and PDGFR-β, with IC50 values of 3, 31, and 90 nM, respectively, inhibited FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10, and showed inhibition of phosphorylated FGFR substrate 2 (pFRS2) and the downstream signaling kinase pERK1/2.
    In Vivo

    Regorafenib mesylate (10 mg/kg, Orally, single dose or daily for 4 days) inhibits tumor vasculature and tumor growth in a rat GS9L glioblastoma model[1].
    Regorafenib mesylate (0-100 mg/kg, Orally, qd × 9) exhibits antitumorigenic and antiangiogenic effects in the Colo-205, MDA-MB-231 and 786-O model[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Rat GS9L glioblastoma xenograft[1]
    Dosage: 10 mg/kg
    Administration: Orally, single dose or daily for 4 days
    Result: Inhibited tumor vasculature and tumor growth in a rat GS9L glioblastoma model.
    Animal Model: Female athymic NCr nu/nu mice, Multiple xenograft models, including models derived from CRC (Colo-205), BC (MDA-MB-231) and RCC (786-O) tumors[1]
    Dosage: 0, 3, 10, 30, 100 mg/kg
    Administration: Orally, qd × 9
    Result: Effectively inhibited growth of the Colo-205, MDA-MB-231 and 786-O model. Significantly reduces tumor MVA, effectively inhibited the RAF/MEK/ERK signaling cascade, and drastically inhibited tumor cell proliferation.
    Clinical Trial
    Molecular Weight

    578.92

    Formula

    C22H19ClF4N4O6S
    CAS No.
    SMILES

    O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F.CS(O)(=O)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Regorafenib mesylate Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Regorafenib835621-08-4BAY 73-4506VEGFRPDGFRRETRafc-KitFGFRAutophagyTieVascular endothelial growth factor receptorPlatelet-derived growth factor receptorRaf kinasesSCFRCD117Fibroblast growth factor receptorAngiopoietin receptorAntitumorigenicantiangiogenictumorHUVECsHep3B cellHAoSMCsNIH-3T3Colo-205MDA-MB-231786-OInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Regorafenib mesylate
    Cat. No.:
    HY-10331B
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.